OBJECTIVES: Conbercept and ranibizumab, the main anti-vascular endothelial growth factor (VEGF) drugs for the treatment of age-related macular degeneration, have been recently approved for reimbursement after health insurance negotiation in china. This study aimed to estimate the budget impact of conbercept and ranibizumab in patients with wet age-related macular degeneration in China. METHODS: A budget impact model with a 5-year time horizon was developed from the perspective of health insurance payer and patients respectively. The model considered 2 scenarios—without and with reimbursement of conbercept and ranibizumab. The reimbursement methods were obtained from the health insurance negotiation outcome. Epidemiology data were used to estimate target population size. Market share in the first year and annual market share growth were derived from IMS data and experts’ opinion. Annual costs of conbercept and ranibizumab were calculated from the drug prices and the annual injection numbers obtained from a meta analysis. Total annual health care costs were estimated based on the target population, the market shares and the annual cost per patient associated with each option, before and after health insurance negotiation. RESULTS: The budget would increase by ¥85.0 million, ¥85.4 million, ¥85.8 million, ¥86.2million and ¥86.6 million during the period of 2018-2022 respectively, which accounted for about 0.005% of the healthcare insurance fund expenditure. Patients’ cost would decrease by ¥134.8million, ¥134.4 million, ¥134.1 million, ¥133.8million and ¥133.4million during the period of 2018-2022 respectively, which accounted for about 53% of patients’ cost without reimbursement. CONCLUSIONS: The introduction of conbercept and ranibizumab to national reimbursement drug list for wet age-related macular degeneration patients would have a minimal incremental budget impact on the overall expenditure and a greatly reduction of patients’ economic burden in China.